Aurinia Pharmaceuticals (NASDAQ:AUPH) appointed Dr. Robert T. Foster, CEO of Hepion Pharmaceuticals, to its board. “As the doctor who discovered voclosporin, and Aurinia’s founder, [Dr. Foster] has a wealth of...
The FDA approved Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) LUPKYNIS(voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis. LUPKYNIS is...
The Phase 2/3 AUDREY clinical study evaluating Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome did not achieve statistical...
The FDA accepted for priority review Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) NDA for voclosporin for the treatment of lupus nephritis (LN). The NDA for voclosporin is based on the Phase 3 AURORA and Phase 2 AURA...
Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) reported positive efficacy and safety results from its AURORA Phase 3 trial of voclosporin, in combination with mycophenolate (MMF) and low-dose corticosteroids, in the...
By Len Zehr As president and CEO of The Lupus Foundation of America (LFA), a role she has held for 15 years, Sandra Raymond is an outspoken advocate for the plight of lupus patients. She has worked with the board of...